COVID-19

CNF has always worked to respond to the greatest needs of the child neurology community. At this time, the greatest need is to provide children and families with neurologic conditions with the supports that they need to care for their children in their homes during a time of social isolation. In response to the COVID-19 pandemic, CNF has pivoted to create targeted resources to support children and families in our community during these unprecedented times.

Message from Child Neurology Foundation’s CEO and Executive Director, Amy Brin.

In March 2020, we released an official statement in collaboration with the Child Neurology Society, to offer links to some official sources like the CDC and FDA. We also released our own statement in how CNF’s work will continue to move forward. As we receive new information, CNF will continue to respond to the greatest needs to help serve the child neurology community. We believe that rising tides lift all boats, and that by working to uplift individuals and organizations across the child neurology landscape, that we will get through this together. Standing in our value of transparency, CNF will continue to provide regular updates to our community via our blog, social media channels (linked on side menu), and newsletters.

This page will act as a jumping off point for CNF’s COVID-19 Content, and other resources that we believe can help the larger child neurology community in the time of COVID-19. Think of this as your one stop shop for resources and supports during the COVID-19 pandemic.

We will get through this together.

null

ORIGINAL CNF COVID-19 CONTENT

Read More

null

EXTERNAL COVID-19 RESOURCES

Read More

null

CNF RISE FAMILY and RISING TIDES GRANTS

Read More

null

CNF’S COVID-19 ADVOCACY

Read More

null

SUPPORT CNF’s COVID-19 RESPONSE

Read More

null

TALK TO A PEER SUPPORT SPECIALIST

Read More

null

ACCESS TO THERAPIES DURING COVID-19

Read More

null

TOGETHER WE WILL GET THROUGH THIS

Read More

CNF thanks our 2020 partners - Biogen, Bluebird Bio, Eisai, Illumina, Inc., Mallinckrodt Pharmaceuticals, Ovid Therapeutics, Retrophin, Inc. and Upsher-Smith Laboratories - for their support.